Smiling woman sitting in front of green wall at AlkermesSmiling woman sitting in front of green wall at AlkermesBlue Triangle graphic

News and Events

Sharing Stories of
Patients, Employees
and Communities

Featured News

Picture of woman at conference

July 28, 2021

Alkermes plc Reports Second Quarter 2021 Financial Results

Read more

Alkermes Inspiration Grants Logo

July 23, 2021

Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program

Read more

Alkermes Sign

June 22, 2021

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

Read more

See all press releases

COVID-19 Response 

In response to the urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our marketed and investigational medicines.

Read our response   

Portrait of woman with mask in research laboratory environment

Alkermes Investor Day

We hosted a virtual Investor Day in March 2021 to discuss our research and development strategy and portfolio, including updates from our nemvaleukin alfa development program in immuno-oncology and new preclinical neuroscience and immuno-oncology programs.

Watch our webcast

HBA Rising Star

We’re proud to recognize Joyanna Wesche-Blake, Senior Director of IT, as our 2021 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.

Learn more

Portrait of smiling Alkermes employee smiling

Blair Jackson in Alkermes office smiling.

In the News

In this “The Medicine Maker” article, our Chief Operating Officer, Blair Jackson, discusses how to determine corporate readiness when exploring a new therapeutic area and reflects on Alkermes' entry into oncology.

Read the article

Media Resources

Company Description

Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.

Media Inquiries

Email our media team

Company Logos


Company Photo


Corporate Fact Sheet


Follow us on our social channels   

blue triangle graphic

Statements and Positions

The idea that a corporation can play a profoundly positive role in society is central to our vision. It is our obligation to voice our beliefs about issues that impact the patients we serve, the communities in which we live and work and society at large.

Access to Medicines

Read more

Marketing Practices

Read more

Systemic Racism and Violence

Read more

Company Response to "Four Good Days"

Read more